EGAGenomicsOtherhttps://ega-archive.org/studies/EGAS00001002597EGAEGA study EGAS00001002597WGS from PDAC samplesGenomic characterization of pancreatic tumours and matched xenograft and organoid models - WGS mapped readsrestrictedEGAPancreatic Carcinomas, Carcinomas, Xenograft, Carcinoma, Xenotransplantation, Cancer of Pancreas, Genomes, Transplantation, Heterograft, Pancreatic Carcinoma, Neoplasms, Acinar Carcinoma, Accessory Genome, familial, Pancreas Cancer, Heterografts, HETEROL TRANSPL, Xenografts, Cancers, TRANSPL HETEROL, Pancreatic Cancers, Transplantations, Pangenome, Pancreas, Pancreas Cancers, Pancreas Neoplasm, Pancreatic Neoplasm, heterologous transplantation, Pancreatic Acinar Carcinoma, Pan-genome, XENOTRANSPL, Xenotransplantations, Organoid, Pancreatic Cancer, Core Genome, Neoplasm, xenotransplant, Pancreatic Acinar, pancreatic tumour., pancreatic carcinoma, Pancreatic, Cancer of the Pancreas, Pancreas Neoplasms, Heterologous Transplantations, Pancreatic Acinar Carcinomas, Heterologous, Acinar Carcinomas, Cancerother disease, Respect, PhrB photolyase activity, Heterograft, neoplasia, Neoplasms, number, Prognostic Factors, TRANSPL HETEROL, photoreactivating enzyme activity, Tumor, Transplantations, pigmented epithelium, presence, heterologous transplantation, NEOPL, Mutations, Personal, diseases, pathogenesis, disease or disorder, diseases and disorders, 3, stratum pigmentosa retinae, NUP96, epithelium, neoplasm, pancreas tubular adenocarcinoma, human disease, MOS3, Prognoses, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, PRECOCIOUS, cell process disease, tumor disease, neoplasm (disease), pigmented retina, Heterografts, F23A5.3, tumour, causes, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, non-neoplastic, genetic, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), pancreatic ductal carcinoma, Xenotransplantations, Organoid, Clients, Personal Respect, causality, disorder, Homo sapiens disease, tumor, constitutitional genetic, SIMPLE, F23A5_3, Neoplastic Growth, Heterologous, Tumors, TP53I7, close to, PRE, pancreatic ductal adenocarcinoma, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, disorders, familial, neoplastic disease, Factor, medical condition, Client, tumours, ductal adenocarcinoma of pancreas, pancreas ductal adenocarcinoma, near to, count in organism, MODIFIER OF SNC1, neoplastic growth, ductal adenocarcinoma of the pancreas, XENOTRANSPL, epithelial, retinal pigment, PIG7, Diseases, deoxyribonucleic photolyase activity, dipyrimidine photolyase (photosensitive), condition, pancreatic duct cancer, Heterologous Transplantations, retinal pigment layer, epitheliocyte, Xenograft, pancreatic duct adenocarcinoma, Xenotransplantation, RPE, Factors, Transplantation, photolyase activity, malignant neoplasm of duct of Wirsung, Prognostic, Dignity, common, HETEROL TRANSPL, patient, Xenografts, whole genome, Pdo, disease of cellular proliferation, cardinality., p. pigmentosa retinae, disease, phr A photolyase activity, DNA-photoreactivating enzyme, pancreatic tubular adenocarcinoma, Patient, approaches, vicinity of, deoxyribonucleate pyrimidine dimer lyase (photosensitive), inherited genetic, other neoplasm, hereditary, NEOPLASMS BENIGN, Neoplasia, Prognostic FactorfalseWhole Genomes Define Concordance in Matched Primary, Xenograft, and Organoid Models of Pancreas CancerPancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of any common solid epithelial tumour. Multiple failed clinical trials necessitate newer approaches to understand the molecular etiology of this disease. Patient-derived xenografts (PDX) and patient-derived organoids (PDO) may serve as pre-clinical disease models; however, characterization remains largely unaddressed at the whole genome level. We conducted a comprehensive assessment of the genetic landscape of tumours and matched PDX and PDO from patients with PDAC. Our data show that PDX and PDO recapitulate PDAC tumourigenesis with respect to simple somatic mutations and copy number changes, and capture major structural variation events.2022-09-20 12:40:56EGAS000010025979606EGAD00001006262EGAD00001003586EGAD00001006152EGAC00001000710